| Drug Name |
Beractant |
| Drug ID |
BADD_D00255 |
| Description |
Beractant is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as SP-B and SP-C. The final composition provides 25 mg/mL phospholipids (including 11.0-15.5 mg/mL disaturated phosphatidylcholine), 0.5-1.75 mg/mL triglycerides, 1.4-3.5 mg/mL free fatty acids, and less than 1.0 mg/mL protein. It is suspended in 0.9% sodium chloride solution, and heat-sterilized.
In anticipation of birth, endogenous lung surfactant is produced to lower the surface tension on alveolar surfaces and to stabilize the alveoli against collapse at resting transpulmonary pressures. However, in Respiratory Distress Syndrome, developmental deficiency of surfactant results collapse of the alveoli causing fast breathing, increased heart rate, apoxia, and sometimes death. Administration of lung surfactant remains the cornerstone of therapy in this condition that is currently the leading cause of death in preterm infants. In comparison to synthetic forms of surfacant, natural forms such as Beractant have been found to have a reduced incidence of pneumothorax and reduced mortality. |
| Indications and Usage |
Beractant is indicated for prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants. |
| Marketing Status |
approved |
| ATC Code |
Not Available |
| DrugBank ID |
DB06761
|
| KEGG ID |
D03096
|
| MeSH ID |
C072197
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D02VLX
|
| NDC Product Code |
0074-1040 |
| UNII |
S866O45PIG
|
| Synonyms |
beractant | surfactant-TA | Survanta |
